Biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tumor necrosis factor-alpha (TNF-α) inhibitors, have revolutionized the treatment of various inflammatory rheumatological conditions, including rheumatoid arthritis and juvenile idiopathic arthritis [2]. Here, TNF is linked to rheumatoid arthritis.